Get the Stockscreener App
5.63
7.44%
0.39
After Hours:
5.65
0.02
+0.36%
Entero Therapeutics Inc stock is traded at $5.63, with a volume of 306.34K.
It is up +7.44% in the last 24 hours and up +78.73% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$5.24
Open:
$5.24
24h Volume:
306.34K
Relative Volume:
0.18
Market Cap:
$8.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+33.73%
1M Performance:
+78.73%
6M Performance:
+381.32%
1Y Performance:
+297.60%
1-Day Range:
$4.75
$5.83
1-Week Range:
$3.85
$5.83
52-Week Range:
$0.9693
$5.83
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
5.63 | 11.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Short interest data insights for Entero Therapeutics Inc.July 2025 Market Mood & Fast Exit Strategy with Risk Control - newser.com
Entero Therapeutics Inc. stock retracement – recovery analysisWeekly Trend Summary & Community Consensus Stock Picks - newser.com
Real time scanner hits for Entero Therapeutics Inc. explained2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Is Entero Therapeutics Inc. stock entering bullish territoryQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Market reaction to Entero Therapeutics Inc.’s recent newsTrade Volume Report & Weekly Market Pulse Updates - newser.com
Visual trend scoring systems applied to Entero Therapeutics Inc.July 2025 Selloffs & Verified High Yield Trade Plans - newser.com
What analysts say about Entero Therapeutics Inc stockPrice Action Trading & Big Gains Small Trading - earlytimes.in
Why Entero Therapeutics Inc. stock is favored by pension fundsWeekly Trade Summary & Community Consensus Picks - newser.com
Is Entero Therapeutics Inc. stock trading near support levelsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - newser.com
Will breakout in Entero Therapeutics Inc. lead to full recoveryJuly 2025 Volume & Verified High Yield Trade Plans - newser.com
Custom watchlist performance reports with Entero Therapeutics Inc.Bear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Will Entero Therapeutics Inc. stock benefit from AI adoption2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Leading vs lagging indicators on Entero Therapeutics Inc. performanceGlobal Markets & AI Enhanced Trading Alerts - newser.com
ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI - Canton Repository
Will Entero Therapeutics Inc. stock outperform international peersWatch List & Safe Capital Investment Plans - newser.com
When is the best time to exit Entero Therapeutics Inc.Portfolio Risk Summary & Stock Market Timing Techniques - newser.com
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus - MSN
Entero Therapeutics acquires AI energy management firm GRID AI By Investing.com - Investing.com Nigeria
Entero Therapeutics acquires grid-edge AI firm GRID AI By Investing.com - Investing.com Canada
Entero Therapeutics acquires grid-edge AI firm GRID AI - Investing.com
Entero Therapeutics acquires AI energy management firm GRID AI - Investing.com India
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand - The Globe and Mail
AI Power Demand Crisis Solution: ENTO Acquires GRID AI's Platform Managing Millions of Energy Assets - Stock Titan
Grid AI Corp. agreed to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - MarketScreener
Published on: 2025-09-30 05:37:04 - newser.com
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):